Investment in ADC Biotechnology by Maven
HMT LLP advised Maven Capital Partners on their investment in anti-cancer drugs manufacturer ADC Biotechnology.
ADC Bio operates in the highest growth sector within oncology therapeutics and has developed a unique patented Lock-Release technology for the development and manufacture of Antibody Drug Conjugates (ADC) group of cancer therapies which are designed to specifically target and kill tumour cells. Known as ‘magic bullets’, ADCs are the next generation of anti-cancer drugs which combine the unique targeting capabilities of anti-bodies with the cancer-killing ability of cytotoxic drugs. The Lock-Release technology facilitates greater production efficiencies and a substantial reduction in the capital cost of manufacturing these drugs for commercial sale.
Maven invested in ADC to help fund the development of an £8 million dedicated pharmaceutical manufacturing facility at a site in Deeside, North Wales, creating 50 new skilled scientific jobs. The investment will allow ADC Bio to move into manufacturing for clinical and commercial use.
HMT undertook financial due diligence on this transaction.
Melanie Goward, Investment Director at Maven commented:
Paul Read commented:
“We are delighted to have advised Maven on another VCT transaction. We look forward to working with them again in the future.”
We are passionate about delivering an optimal outcome for our clients and helping them achieve their personal objectives. We understand entrepreneurial businesses because we are one
Partners are supported by high-calibre professional staff who share our core values of enthusiasm, energy, entrepreneurialism and empathy to our client’s objectives
Our Partners have unparalleled deal experience in the mid-market and are supported by a team of dedicated deal-doers with specialist capabilities and experience